The low-cost, scalable technology solution will help mitigate antimicrobial resistance in Nigeria.

The four-year, $26.5 million grant will help minimize the impact of antimalarial drug resistance.

New digital and in-person resources prepare health workers to deliver the full range of WHO-approved PrEP methods, including oral PrEP, DVR, CAB-LA, and Lenacapavir.

Jhpiego will receive an additional US$2.3 million in funding to integrate the calibrated drape into existing programs in the Democratic Republic of Congo, Guinea and India, and support catalytic procurement in Rwanda.

The Pfizer Foundation progressed a three-year $15 million initiative to help improve the lives of women with breast cancer in Rwanda, Ghana, and Tanzania.